Insights

Key Leader Appointment GenEdit appointed J. Rodrigo Mora as Chief Scientific Officer, indicating potential research collaborations and sales opportunities with Mora's network and expertise.

Strategic Partnerships GenEdit collaborating with Genentech to develop nucleic acid-based medicines for autoimmune diseases presents sales opportunities for joint product development and market expansion.

Promising Technology Adoption Sarepta Therapeutics leveraging GenEdit's polymer nanoparticle delivery system for gene-editing therapies signals potential sales growth through technology licensing and co-development ventures.

Venture Funding and Investor Confidence GenEdit securing $26 million in Series A financing, with support from Eli Lilly and Sequoia Capital, showcases financial stability and potential for sales growth, attracting further investment and partnerships.

Competitive Landscape Positioning GenEdit's focus on genetic medicine delivery and its partnerships with industry leaders like Sarepta highlights a competitive edge, offering unique sales propositions to cater to unmet medical needs in the market.

GenEdit Tech Stack

GenEdit uses 8 technology products and services including Google Analytics, Cloudflare, Google Font API, and more. Explore GenEdit's tech stack below.

  • Google Analytics
    Analytics
  • Cloudflare
    Content Management System
  • Google Font API
    Font Scripts
  • Polymer
    Javascript Frameworks
  • Lightbox
    Javascript Libraries
  • Open Graph
    Miscellaneous
  • Webpack
    Miscellaneous
  • Kinsta
    Platform As A Service

Media & News

GenEdit's Email Address Formats

GenEdit uses at least 1 format(s):
GenEdit Email FormatsExamplePercentage
FLast@genedit.comJDoe@genedit.com
90%
Last@genedit.comDoe@genedit.com
7%
First@genedit.comJohn@genedit.com
2%
FirstL@genedit.comJohnD@genedit.com
1%

Frequently Asked Questions

Where is GenEdit's headquarters located?

Minus sign iconPlus sign icon
GenEdit's main headquarters is located at 681 Gateway Blvd Suite 313 South San Francisco, California 94080 US. The company has employees across 1 continents, including North America.

What is GenEdit's official website and social media links?

Minus sign iconPlus sign icon
GenEdit's official website is genedit.com and has social profiles on LinkedIn.

How much revenue does GenEdit generate?

Minus sign iconPlus sign icon
As of September 2024, GenEdit's annual revenue reached $3.8M.

What is GenEdit's SIC code NAICS code?

Minus sign iconPlus sign icon
GenEdit's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does GenEdit have currently?

Minus sign iconPlus sign icon
As of September 2024, GenEdit has approximately 46 employees across 1 continents, including North America. Key team members include Chief Executive Officer & Co-Founder: K. L.Chief Technology Officer: T. C. F.Chief Scientific Officer: T. F.. Explore GenEdit's employee directory with LeadIQ.

What industry does GenEdit belong to?

Minus sign iconPlus sign icon
GenEdit operates in the Biotechnology Research industry.

What technology does GenEdit use?

Minus sign iconPlus sign icon
GenEdit's tech stack includes Google AnalyticsCloudflareGoogle Font APIPolymerLightboxOpen GraphWebpackKinsta.

What is GenEdit's email format?

Minus sign iconPlus sign icon
GenEdit's email format typically follows the pattern of . Find more GenEdit email formats with LeadIQ.

How much funding has GenEdit raised to date?

Minus sign iconPlus sign icon
As of September 2024, GenEdit has raised $24M in funding. The last funding round occurred on Jan 23, 2024 for $24M.

When was GenEdit founded?

Minus sign iconPlus sign icon
GenEdit was founded in 2016.
GenEdit

GenEdit

Biotechnology ResearchCalifornia, United States11-50 Employees

GenEdit is focused on overcoming the major challenge to genetic medicines:  Delivery. We aim to overcome this limitation and enable treatment of a broad range of diseases, having a positive impact on the lives of as many people as possible.  

The foundation of our company is our NanoGalaxy platform. NanoGalaxy contains a library spanning thousands of unique non-viral, non-lipid, polymer nanoparticles. Using our iterative screening process, we are able to identify polymer nanoparticles that can deliver the needed genetic medicine payload to the needed tissue to treat disease.

We are focusing our research on the treatment of diseases for which our delivery technology can enable therapeutic options that otherwise may not be possible. We are developing an internal pipeline of therapeutic candidates to treat a range of diseases with high unmet medical need.

Section iconCompany Overview

Headquarters
681 Gateway Blvd Suite 313 South San Francisco, California 94080 US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $24M

    GenEdit has raised a total of $24M of funding over 7 rounds. Their latest funding round was raised on Jan 23, 2024 in the amount of $24M.

  • $10M

    GenEdit's revenue is in the range of $10M

Section iconFunding & Financials

  • $24M

    GenEdit has raised a total of $24M of funding over 7 rounds. Their latest funding round was raised on Jan 23, 2024 in the amount of $24M.

  • $10M

    GenEdit's revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.